Interview: Boehringer Ingelheim's Heidi Hunter on biosimilar originality, jousting and getting to market
German family-owned drug major Boehringer Ingelheim has been in the biosimilars business since the end of 2011 when it developed what was effectively a startup within the company to manufacture a new kind of therapy. What it now has in 2015 is a portfolio of biosimilar products, three of which are in Phase III.
Heidi Hunter, senior vice president and head of Boehringer Ingelheim’s global biosimilar business, talked to TPL about the particularities of developing biosimilars, and what the company’s plans are for the near future.
“We have biosimilars to Humira (adalimumab), Avastin (bevacizumab) and Rituxan (rituximab), and those would be the first biosimilars that Boehringer Ingelheim would come to the market with,” she said, with the Humira molecule first on the horizon, and a freedom-to-operate date at the end of 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze